CLAIMS

1. Use of a compound in the manufacture of a medicament for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck in a patient, wherein the compound is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof.

2. Use according to claim 1, wherein the recurrent and/or metastatic squamous cell carcinoma of the head and neck is recurrent squamous cell carcinoma of the head and neck.

3. Use according to claim 2, wherein the recurrent squamous cell carcinoma of the head and neck is metastatic recurrent squamous cell carcinoma of the head and neck.

4. Use according to any one of claims 1 to 3, wherein treating recurrent and/or metastatic squamous cell carcinoma of the head and neck comprises reducing the size of a tumour associated with the recurrent and/or metastatic squamous cell carcinoma of the head and neck.

5. Use according to claim 4, wherein the size of the tumour is reduced from base line by at least 10%,

optionally wherein the size of the tumour is as measured in accordance with version 1.1 of the RECIST criteria.

6. Use according to any one of the preceding claims, wherein the recurrent and/or metastatic squamous cell carcinoma of the head and neck is resistant to radiotherapy and/or chemotherapy.

7. Use of a compound in the manufacture of a medicament for treating head and neck cancer in a patient, wherein:

the compound is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof; and

treating the head and neck cancer comprises reducing the size of one or more tumours associated with the head and neck cancer.

8. Use according to claim 7, wherein the head and neck cancer is recurrent head and neck cancer.

9. Use according to claim 7 or claim 8, wherein the head and neck cancer is metastatic.

10. Use according to any one of claims 7 to 9, wherein the head and neck cancer is squamous cell carcinoma of the head and neck.

11. Use according to any one of claims 7 to 10, wherein the size of the tumour is reduced from base line by at least 10%,

optionally wherein the size of the tumour is as measured in accordance with version 1.1 of the RECIST criteria.

12. Use according to any one of claims 7 to 11, wherein the head and neck cancer is resistant to radiotherapy and/or chemotherapy.

13. Use according to any one of the preceding claims, wherein the patient has received at least one line of cancer therapy prior to treatment with the compound.

14. Use according to any one of the preceding claims, wherein the patient has received at least two lines of cancer therapy prior to treatment with the compound.

15. Use according to any one of the preceding claims, wherein the patient is a human patient.

16. Use according to any one of the preceding claims, wherein the patient is male or female.

17. Use according to any one of the preceding claims, wherein the patient is male

18. Use according to any one of the preceding claims, wherein the age of the patient is from 18 to 90 years.

19. Use according to any one of the preceding claims, wherein the age of the patient is from 30 to 70 years.

20. Use according to any one of the preceding claims, wherein the compound is NRC-2694 dihydrochloride (NRC-2694-A) or NRC-2694 monohydrochloride (NRC-2694-B).

21. Use according to any one of the preceding claims, wherein the compound is NRC-2694 dihydrochloride (NRC-2694-A).

22. Use according to any one of the preceding claims, wherein the compound is administered to the patient orally.

23. Use according to any one of the preceding claims, wherein the compound is administered to the patient in the form of a tablet or a capsule.

24. Use according to any one of the preceding claims, wherein the compound is administered to the patient once or twice daily.

25. Use according to any one of the preceding claims, wherein the compound is administered to the patient once daily.

26. Use according to any one of the preceding claims, wherein the compound is administered to the patient in a dose of from 50 mg/day to 500 mg/day.

27. Use according to any one of the preceding claims, wherein the compound is administered to the patient in a dose of from 100 mg/day to 400 mg/day.

28. Use according to any one of the preceding claims, wherein the compound is used in combination with (a) cisplatin and paclitaxel or (b) carboplatin and paclitaxel.

29. Use of a compound in the manufacture of a medicament for the treatment of recurrent squamous cell carcinoma of the head and neck in a patient, which compound is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof.